Short Interest in ADMA Biologics, Inc. (NASDAQ:ADMA) Drops By 9.3%

ADMA Biologics, Inc. (NASDAQ:ADMA) was the target of a large decline in short interest in November. As of November 30th, there was short interest totalling 12,910,000 shares, a decline of 9.3% from the November 15th total of 14,240,000 shares. Based on an average trading volume of 4,970,000 shares, the days-to-cover ratio is presently 2.6 days.

Insider Transactions at ADMA Biologics

In related news, CFO Brad L. Tade sold 15,000 shares of the firm’s stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total transaction of $317,250.00. Following the completion of the sale, the chief financial officer now directly owns 199,433 shares of the company’s stock, valued at $4,218,007.95. This trade represents a 7.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.70% of the stock is owned by company insiders.

Institutional Trading of ADMA Biologics

A number of institutional investors have recently bought and sold shares of the business. Quest Partners LLC acquired a new position in shares of ADMA Biologics in the 2nd quarter valued at $29,000. Hollencrest Capital Management bought a new stake in ADMA Biologics in the third quarter valued at about $30,000. Larson Financial Group LLC acquired a new position in ADMA Biologics in the third quarter valued at about $31,000. National Bank of Canada FI acquired a new position in ADMA Biologics in the third quarter valued at about $35,000. Finally, Harvest Fund Management Co. Ltd bought a new position in ADMA Biologics during the third quarter worth about $62,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

Analyst Ratings Changes

ADMA has been the subject of a number of research reports. Raymond James raised their target price on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research note on Friday, November 8th. HC Wainwright increased their price objective on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $20.00 target price on shares of ADMA Biologics in a research note on Friday, September 20th.

ADMA Biologics Stock Down 0.4 %

NASDAQ ADMA opened at $18.59 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. ADMA Biologics has a 52 week low of $3.95 and a 52 week high of $23.64. The stock has a market capitalization of $4.39 billion, a P/E ratio of 66.39 and a beta of 0.70. The stock has a fifty day moving average of $19.02 and a 200-day moving average of $16.05.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The company had revenue of $119.84 million for the quarter, compared to analyst estimates of $107.25 million. During the same quarter last year, the firm earned $0.01 EPS. On average, equities research analysts forecast that ADMA Biologics will post 0.52 EPS for the current year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.